KPC PharmaceuticalsInc Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO

KPC PharmaceuticalsInc has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Ting Guo	Director	1.5yrs	no data	no data
Hui Zhou	Director	less than a year	no data	no data
Huawei Qiu	Chairman	1.5yrs	no data	no data
Jin Guo Xin	Independent Director	2.6yrs	CN¥100.00k	no data
Ke Liu	Independent Director	5.7yrs	CN¥100.00k	no data
Zheng Liang	Director	1.5yrs	no data	no data
Li Lin Xi	Employee Supervisor	5.7yrs	no data	no data
Zhang Weng Sen	Employee Supervisor	5.7yrs	no data	no data
Hongshen Li	Vice Chairman	less than a year	no data	no data
Zhi Yang	Independent Director	2.6yrs	CN¥100.00k	no data
Kang Deng	Supervisor	3.3yrs	no data	no data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Board: 600422's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

KPC PharmaceuticalsInc Management

Management criteria checks 0/4

Key information

Recent management updates

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.51 in FY 2022)

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.67 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Board Members

Average Tenure

Average Age